Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 194

recruiting
3 977
countries
28
conditions
2 105

3 664 trials match your criteria

Cholangiocarcinoma

Not recruiting

Study of Pemigatinib for Patients with Advanced Intrahepatic Cholangiocarcinoma with FGFR2 Changes After Local Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pemigatinib

Study on the Effects of Risankizumab in Patients with Very Early Axial Spondyloarthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Risankizumab

Study on Budesonide Tablets for Treating Eosinophilic Esophagitis in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide

Study on Itepekimab for Former Smokers with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab

Study of Pembrolizumab with Radiotherapy for Patients with Recurrent Prostate Cancer After Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Study of Latozinemab for Patients with Neurodegenerative Diseases Who Previously Participated in a Latozinemab Study

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Latozinemab

Cardiac failure+1

Not recruiting

Study on the Effects of Ferric Derisomaltose on Cognitive Function in Heart Failure Patients with Iron Deficiency

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ferric Derisomaltose

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Alport's syndrome

Not recruiting

Study on the Safety of Vonafexor for Patients with Alport Syndrome at Risk of Progression

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Vonafexor

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Itolizumab

Neuroblastoma+1

Not recruiting

Study of Palbociclib with Drug Combinations for Children and Young Adults with Recurrent or Refractory Neuroblastoma and Ewing Sarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Palbociclib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.